Immuneering (IMRX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Immuneering (IMRX) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.27 of bullish evidence against -0.27 bearish.

Immuneering last closed at $4.04, -0.74% on the session.

Against the IVW growth benchmark the position is -1.66% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

14 graded predictions for IMRX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Immuneering in the 24th percentile on return on equity, where 100 is best.

Immuneering is classified under Health Care / Biotechnology, with a market capitalisation of $263.32M.

StockMap tracks Immuneering as the 208th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Immuneering ranks 229th of 344 in the group, against a group median of -0.21.